RT Journal Article
T1 Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
A1 Couñago, F
A1 Rodriguez de Dios, N
A1 Montemuiño, S
A1 Jové-Teixidó, J
A1 Martin, M
A1 Calvo-Crespo, P
A1 López-Mata, M
A1 Samper-Ots, M P
A1 López-Guerra, J L
A1 García-Cañibano, T
A1 Díaz-Díaz, V
A1 de Ingunza-Barón, L
A1 Murcia-Mejía, M
A1 Alcántara, P
A1 Corona, J
A1 Puertas, M M
A1 Chust, M
A1 Couselo, M L
A1 Del Cerro, E
A1 Moradiellos, J
A1 Amor, S
A1 Varela, A
A1 Thuissard, I J
A1 Sanz-Rosa, D
A1 Taboada, B
K1 Chemoradiation
K1 NSCLC
K1 Neoadjuvant treatment
K1 Surgery
K1 stage IIIA
AB The role of surgery in stage IIIA-N2 non-small cell lung cancer (NSCLC) is an actively debated in oncology. To evaluate the value of surgery in this patient population, we conducted a multi-institutional retrospective study comparing neoadjuvant chemoradiotherapy or chemotherapy plus surgery (CRTS) to definitive chemoradiotherapy (dCRT). A total of 247 patients with potentially resectable stage T1-T3N2M0 NSCLC treated with either CRTS or dCRT between January 2005 and December 2014 at 15 hospitals in Spain were identified. A centralized review was performed to ensure resectability. A propensity score matched analysis was carried out to balance patient and tumor characteristics (n = 78 per group). Of the 247 patients, 118 were treated with CRTS and 129 with dCRT. In the CRTS group, 62 patients (52.5%) received neoadjuvant CRT and 56 (47.4%) neoadjuvant chemotherapy. Surgery consisted of either lobectomy (97 patients; 82.2%) or pneumonectomy (21 patients; 17.8%). In the matched samples, median overall survival (OS; 56 vs 29 months, log-rank p = .002) and progression-free survival (PFS; 46 vs 15 months, log-rank p  The findings reported here indicate that neoadjuvant chemotherapy or chemoradiotherapy followed by surgery (preferably lobectomy) yields better OS and PFS than definitive chemoradiotherapy in patients with resectable stage IIIA-N2 NSCLC.
YR 2018
FD 2018-02-14
LK http://hdl.handle.net/10668/12269
UL http://hdl.handle.net/10668/12269
LA en
DS RISalud
RD Apr 6, 2025